[zino]

makinezmoney, Yes it has major potential indeed

[zino]

Any news will erupt this...imo

[rib eye]

Not many shares out there:
Outstanding:8.45m
Float: 3.45m

won't take much to push it up fast

https://www.marketwatch.com/investing/stock/ccel?mod=over_search

[rib eye]

No complaints here. Either way it was a very solid day for this stock

[MinookaJoe]

I'll take it....hopefully this bodes well going forward!

[rib eye]

I saw thst too. Went from 13.50ish to 14.16 a minute before close

[MinookaJoe]

14.16 close.....is this correct???

[bosman]

Low float stock here. This will go much higher I'm Holden and buying.

[bosman]

Looks good here

[Paul Brentjens]

nice if you compare the 2 (revenues, profits, cash, etc.), it should go even higher than that

[makinezmoney]

$CCEL: We'll be at $20 soon enough......


If a turd like $FCUV can go........... this is a shoo-in



GO $FCEL

[makinezmoney]

$CCEL: Looks very thin $15 on L2


less than 1k shares


WOW............. ready to bust out



GO $CCEL

[makinezmoney]

$CCEL: $13.50 just hit.............


What did I tell you....... the next $FCUV ????


I don't see why not.


I love this slowwwwwwwww steady action.


Just how you wanna see the early accumulation happening.


GO $CCEL

[makinezmoney]

$CCEL: Fair close.... 12.30


$FCUV stole all our thunder.


Stilllllllllllllll........... more revs here than $FCUV.


They'll find it eventually.


It just got uplisted so let it simmer a bit



GO $CCEL

[bosman]

You are doing beautifully

[makinezmoney]

$CCEL: The "UPSIDE-HALT-SHOW is about to BEGIN" here



Got 3k at 11.75 today so far.... will add more


L2 looks gorgeous on the ask side all the way to $15 here



GO $CCEL

[bosman]

I missed MTRT & FCUV. Not missing CCEL

[makinezmoney]

$CCEL: Awesome... I got in $MTRT at $0.17


Almost hit $2 this morning.... not done yet.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165689743


Wait till they find out where I am today.


$FCUV sky-rocketed to $24 from $6 today with that uplist from OTC
to now NASdaq and if you look at the float here, its
much much less than that with $30Milly in REVS.


They might dispute it but when this gets to over $20 shortly, they'll
figure out why we're here :)


This is prime for a RUNNER


Now at $12


GO $CCEL

[bosman]

Bought me a starter here today.

[makinezmoney]

$CCEL: $30Milly in Annual Revs, $8.5Milly CASH

https://d1io3yog0oux5.cloudfront.net/_869e1efa55917fa6aa95600eb7b126b9/cryocell/db/1159/10590/pdf/2021+08_13+Cryo-Cell+IR+presentation+%281%29.pdf


Definitely keep this on your radar.


Float is much smaller than $FCUV that ran today



GO $CCEL

[makinezmoney]

$CCEL : Uplisted to NAS.... just like $FCUV


https://www.otcmarkets.com/filing/pdf?id=15198534&guid=Rps9kp4gOAvSqth



Float only 10 Milly ????????

Don't confuse CEO with Portnoy from Barstool Sports fame.

https://ir.cryo-cell.com/company-information/management-team


Now at 11.75



GO $CCEL



******************************************************************


Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market
9:00 AM ET 8/30/21 | GlobeNewswire

Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market

Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Company's Common Stock Has Been Approved For Listing On The Nasdaq Capital Market ("Nasdaq").

Trading to Begin August 31, 2021 with Current Ticker "CCEL"

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International has met Nasdaq's stringent financial, liquidity and corporate governance listing requirements. As a result, Cryo-Cell will be listed on Nasdaq as of Tuesday, August 31(st) 2021. This is expected to improve the liquidity of Cryo-Cell common stock, broaden its institutional shareholder base and ultimately enhance long-term shareholder value.

Cryo-Cell's Chairman of the Board and Co-Chief Executive Officer, David Portnoy, stated: "I am pleased to announce Cryo-Cell's uplisting to Nasdaq, a major financial milestone that the Company had been considering, as previously stated several months ago. I believe that the significant gap between Cryo-Cell's current market valuation and our intrinsic value should narrow as our visibility in the investment community grows, and this is a step in that direction." Cryo-Cell International has transformed in 2021 from being a profitable cord blood bank to a fully integrated, biopharmaceutical company that is expected to provide much needed access to experimental treatments for patients at the upcoming Cryo-Cell Institute for Cellular Therapies.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby's cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell's public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as Cedars--Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell's facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell owns the exclusive rights to PrepaCyte-CB, the industry's most advanced cord blood processing technology.

Cryo-Cell's mission has been to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby's cord blood and support the advancement of regenerative medicine. In February 2021, Cryo-Cell entered into a license agreement with Duke University that transformed Cryo-Cell into an autonomous, vertically integrated cellular therapy company that will be able to treat patients.

For more information, please visit IR.cryo-cell.com

Forward-Looking Statement

Statements herein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the success of the Company's initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

For more information, please contact:

Corporate Communications / Investor Relations

Diane Glanz, Rph, PharmD.

Telephone: [phone]

Email: [e-mail]

> Dow Jones Newswires

August 30, 2021 09:00 ET (13:00 GMT)

[Renee]

CCEL moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Dendyst]

Hi, any news about this stock? It seems blocked, I can’t even sell my shares on trading212

[Golden Cross]

CCEL Daily Chart

[Golden Cross]

News Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2019 Financial Results


October 15, 2019 16:30 ET | Source: Cryo-Cell International, Inc.
OLDSMAR, Fla., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2019.

Financial Results

Revenue

Consolidated revenues for the third quarter of fiscal 2019 were $8.2 million compared to $7.9 million for the third quarter of fiscal 2018. The revenues for the third quarter of fiscal 2019 consisted of $7.6 million in processing and storage fees, $423,173 in licensee income, $33,035 in product revenue and $160,561 in public banking revenue compared $7.2 million in processing and storage fees, $539,286 in licensee income, $29,308 in product revenue and $65,575 in public banking revenue for the third quarter of fiscal 2018.

Net Income

The Company reported net income for the three months ended August 31, 2019 of $1,116,000, or $0.14 per basic share and $0.13 per diluted share, compared to net income of $245,000, or $0.03 per basic and diluted share for the three months ended August 31, 2018. Net income for the three months ended August 31, 2019 resulted from a 4% increase in revenue and a 19% decrease in selling, general and administrative expenses offset by a 4% increase in cost of sales. The decrease in selling, general and administrative expenses is due in part to $580,000 of expenses related to the Cord:Use purchase during the third quarter of fiscal 2018. These expenses were non-recurring expenses related to the acquisition of Cord:Use.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its family bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S. in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.

[Termite7]

Link? Thanks!!!

[boardbrain1]

CCEL is dumping CBAI, GL with this.

[Epic]

CCEL is buying CBAI on the open market

https://ih.advfn.com/p.php?pid=nmona&article=76805667

[Agent92260]

Investors selling after insider selling a modest 9k shares? Not sure if they are connected but stock dipping regardless.

[locksflooring]

Great volume! Maybe CCEL IS BUYING MORE CBAI STOCK WITH THE HUGE AMOUNT OF CCEL BUYING! Cryo-cell Internatio (CCEL)
4.01 ? 0.0 (0.00%)
Volume: 50 @ 11:43:07 AM ET

[Agent92260]

Ok. I'm out at $4. GL everyone.

[Agent92260]

Yes and they can purchase mine in the process.

[Diana15]

Could be. The largest stockholder of CCEL may have been an obstacle. Possibly there was a agreement that before any merger agreement can be made, the 25% holder of CCEL stock had to go. CCEL paying a larger premium above the market price, indicates they wanted them gone badly.Now they can move forward after the closing date for the purchase of shares from Ki Yong Choi and Michael Cho (the “Sellers”).

[Agent92260]

Thanks. Still looking forward to a merge of both Cord Blood/BioBanks. See no reason why not. I think all parties are just waiting for the other to come a little closer to desired SP. Feels very close now, IMO.

[Diana15]

Looks like a good purchase move on your part.Should do well.

[Agent92260]

Yes. I purchased a modest 500 on June 1. Looking good so far.

[Diana15]

Apparently it was. Today so far it is 3.56 Up 0.49(15.88%) 1:17PM EDT. 9 times the 3 month avg volume.

[Diana15]

Is it time to buy CCEL? The company just purchased appox. 25% of their own stock for $4.50 a share. That's a 46.6% premium over the closing price today of $3.07. Did they want to get rid of their largest stockholder (who once had a lawsuit with DAVID I. PORTNOY, MARK L. PORTNOY,, or do they believe the stock is much undervalued.

From CCEL's 8K filed today.

"Stock Purchase Agreement. On June 20, 2016, Cryo-Cell International, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Agreement”) with Ki Yong Choi and Michael Cho (the “Sellers”), collectively the parties (the “Parties”). Pursuant to the Agreement, the Company will purchase 2,179,068 Shares from Ki Yong Choi and 13,416 Shares from Michael Cho (the “Shares”) for $4.50 per share, $9,866,178 in the aggregate (the “Purchase Price”), to be funded through the proceeds of a term loan for approximately $8 million in senior credit facilities and the remainder through the working capital of the Company."

[Myth]

No truth to that at all....

[worthylion]

That accounting reversal is required by auditors if there have been enough successive Qs of profitability and continued profitability is expected--just as the last reversal was required after too many Qs of losses. Not a management decision so you're reading too much into it.

[junebug6500]

I'm changing my thoughts once again. The other scenario that makes sense is CCEL plans to sell their assets which renders the Income Tax benefit useless. So why not take it now.

[junebug6500]

And for the record if I'm correct with this scenario, I don't think it's CBAI trying to do something with CCEL. Most likely another pharmaceutical company like AMAG. Fun speculating which is all this is.

[junebug6500]

I know this is going to sound crazy but it's my best thinking at this point. IMO the taking of a nearly $7M Income Tax benefit in CCEL's 3rd Quarter financials is a defensive move. Some mergers are done partially to claim an Income Tax benefit in the new combined company. Is/was someone planning to attempt a hostile takeover of CCEL? I'm otherwise totally baffled by this move. Anyone have any other thoughts? Very unusual for a company to take such a huge move in the 3rd Qtr. They also added $1.5M of Goodwill not previously claimed. We may find out something soon or never know anything more. But there was a reason for this now rather than later for sure.

[Enterprising Investor]

CRYO-CELL, CORD BLOOD BANKING COMPANY, ANNOUNCES FINAL RESULTS OF ITS TENDER OFFER (7/30/15)

OLDSMAR, Fla. – July 30, 2015 – Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today final results of its tender offer to purchase up to 750,000 shares of its common stock at a price of $3.25 per share, which expired at 12:00 midnight, New York City time on Tuesday, July 28, 2015.

Based on the tabulation by Continental Stock Transfer and Trust Company, the Depositary for the tender offer, 558,502 shares of CCEL common stock were properly tendered and not withdrawn. CCEL accepted for purchase 558,502 shares of its common stock, including all “odd lots” properly tendered, at a purchase price of $3.25 per share, for an aggregate cost of $1,815,132 excluding fees and expenses relating to the tender offer.

The shares purchased in the tender offer represent approximately 5.8% of CCEL’s outstanding common stock (including shares of unvested restricted stock) prior to completion of the purchase.

The Depositary will promptly issue payment for the shares validly tendered and accepted for purchase.

After giving effect to the purchase of shares in the tender offer and the exercise of options to purchase 25,000 shares during July 2015, CCEL will have 9,132,032 shares of its common stock outstanding (including shares of unvested restricted stock).

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members’ stem cells. Cryo-Cell’s mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.

[worthylion]

They're otcbb listed. They do file financials with the SEC quarterly so aren't a pink sheet company that doesn't file.